Tonghua Dongbao Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

De CEO Tonghua Dongbao Pharmaceutical's is Sheng Leng Chun, benoemd in May2020, heeft een ambtstermijn van 4.42 jaar. bezit rechtstreeks 0.12% van de aandelen van het bedrijf, ter waarde CN¥ 20.00M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.4 jaar en 4.4 jaar.

Belangrijke informatie

Sheng Leng Chun

Algemeen directeur

CN¥3.7m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.4yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	4.4yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

CEO

Sheng Leng Chun (50 yo)

4.4yrs

Tenure

CN¥3,728,800

Compensatie

Mr. Chun Sheng Leng serves as a Director and General Manager since Mach 27, 2024 and served as the Chairman and General Manager at Tonghua Dongbao Pharmaceutical Co., Ltd. since May 7, 2020 until March 27,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sheng Leng Chun	GM & Director	4.4yrs	CN¥3.73m	0.12% CN¥ 18.0m
Junyu Chi	Chief Accountant	4.4yrs	CN¥852.40k	geen gegevens
Hong Chen	Chief Engineer & Deputy GM	10.6yrs	CN¥527.20k	0.015% CN¥ 2.3m
Guodong Zhang	Deputy GM & Director	4.4yrs	CN¥1.17m	0.013% CN¥ 2.1m
Wenhai Zhang	Deputy GM & Director	4.4yrs	CN¥1.17m	0.030% CN¥ 4.7m
Zhiqiang Du	Deputy General Manager	2.9yrs	CN¥1.45m	geen gegevens
Fan Su	Deputy GM & Board Secretary	4.3yrs	CN¥992.50k	geen gegevens

4.4yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 600867 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sheng Leng Chun	GM & Director	10.6yrs	CN¥3.73m	0.12% CN¥ 18.0m
Guodong Zhang	Deputy GM & Director	4.4yrs	CN¥1.17m	0.013% CN¥ 2.1m
Wenhai Zhang	Deputy GM & Director	4.4yrs	CN¥1.17m	0.030% CN¥ 4.7m
Junye Wang	Chairman of the Supervisory Board	4.1yrs	CN¥1.17m	0.12% CN¥ 18.3m
Fu Bo Cao	Supervisor	4.4yrs	CN¥173.20k	geen gegevens
Wei Wang	Director	4.1yrs	geen gegevens	geen gegevens
Qingxia He	Employee Representative Supervisor	4.4yrs	geen gegevens	geen gegevens
Jiahong Li	Chairman of the Board	4.4yrs	CN¥173.20k	0.27% CN¥ 41.8m
Yan Bi	Independent Director	9.3yrs	CN¥100.00k	geen gegevens
Dai Xu	Independent Director	2.4yrs	CN¥100.00k	geen gegevens
Li Xu	Independent Director	2.4yrs	CN¥100.00k	geen gegevens
Jianchun Zhen	Director	1.1yrs	geen gegevens	geen gegevens

4.4yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 600867 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Tonghua Dongbao Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 16%

New minor risk - Profit margin trend

Now 21% overvalued

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) announces an Equity Buyback for CNY 120 million worth of its shares.

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.13 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 08, 2024

Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao

Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 2Q 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.64 in FY 2021)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.64 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 2Q 2021)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback for CNY 360 million worth of its shares, under the authorization approved on March 25, 2022.

First quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.17 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.64 (vs CN¥0.46 in FY 2020)

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

An unknown buyer signed an agreement to acquire 5% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) from Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) for CNY 460 million.

Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) dropped from FTSE All-World Index (USD)

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 3Q 2020)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback Plan for 24,000,000 shares, representing 1.18% for CNY 360 million, under the authorization approved on August 25, 2021.

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.13 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.46 (vs CN¥0.40 in FY 2019)

New 90-day low: CN¥11.82

Revenue misses expectations

Full year 2020 earnings released: EPS CN¥0.46

New 90-day low: CN¥12.87

New 90-day low: CN¥13.32

New 90-day high: CN¥14.91

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Earnings released

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd